Alogliptin benzoate for the treatment of type 2 diabetes

Alogliptin: a new addition to the class of DPP-4 inhibitors

(2016) Marc Rendell   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks

(2011) Antonio R Chacra et al.   Diabetes & Vascular Disease Research

Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus

(2011) Priscilla L Hollander et al.   Diabetes & Vascular Disease Research

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects

(2011) A. Karim et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

The Safety of Incretin-Based Therapies—Review of the Scientific Evidence

(2011) Daniel J. Drucker et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Linagliptin: A New DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

(2011) Peter P. Toth   POSTGRADUATE MEDICINE

Efficacy and Safety of Saxagliptin Combination Therapy in US Patients with Type 2 Diabetes

(2011) Chetan Karyekar et al.   POSTGRADUATE MEDICINE

Saxagliptin: A New Dipeptidyl Peptidase 4 Inhibitor for Type 2 Diabetes

(2010) N. L. Borja-Hart et al.   ANNALS OF PHARMACOTHERAPY

Dipeptidylpeptitase-4 Inhibitors (Gliptins)

(2010) André J. Scheen   CLINICAL PHARMACOKINETICS

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects

(2010) Akiko Sarashina et al.   CLINICAL THERAPEUTICS

Counterpoint: Intensive Glucose Control and Mortality in ACCORD--Still Looking for Clues

(2010) M. C. Riddle   DIABETES CARE

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

(2010) André J. Scheen et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

(2010) T. Forst et al.   DIABETIC MEDICINE

Alogliptin

(2010) Lesley J. Scott   DRUGS

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

(2010) B. Göke et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

(2010) Faramarz Ismail-Beigi et al.   LANCET

Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus

(2009) Joshua J Neumiller et al.   ANNALS OF PHARMACOTHERAPY

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2009) Richard E. Pratley et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study

(2009) Debora Williams-Herman et al.   CURRENT MEDICAL RESEARCH AND OPINION

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia

(2009) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

(2009) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

(2009) E. Bosi et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

(2009) R. E. Pratley et al.   DIABETES OBESITY & METABOLISM

Coadministration of Pioglitazone or Glyburide and Alogliptin: Pharmacokinetic Drug Interaction Assessment in Healthy Participants

(2009) Aziz Karim et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Clinical Studies of Liraglutide, a Novel, Once-Daily Human Glucagon-Like Peptide-1 Analog for Improved Management of Type 2 Diabetes Mellitus

(2009) Scott R Drab   PHARMACOTHERAPY

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

(2008) P COVINGTON et al.   CLINICAL THERAPEUTICS

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

(2008) Ralph A. DeFronzo et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

(2008) Itamar Raz et al.   CURRENT MEDICAL RESEARCH AND OPINION

Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials

(2008) Avraham Karasik et al.   CURRENT MEDICAL RESEARCH AND OPINION

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

(2008) Sten Madsbad et al.   CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study

(2008) R. A. DeFronzo et al.   DIABETES CARE

Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited

(2008) B. F. Burkey et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*

(2008) R. Scott et al.   DIABETES OBESITY & METABOLISM

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

(2008) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Vildagliptin

(2008) Jamie D Croxtall et al.   DRUGS

Efficacy and Safety of Vildagliptin Monotherapy during 2-Year Treatment of Drug-naïve Patients with Type 2 Diabetes: Comparison with Metformin

(2008) B. Göke et al.   HORMONE AND METABOLIC RESEARCH

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

(2008) M. A. Nauck et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

The Role of Incretins in Glucose Homeostasis and Diabetes Treatment

(2008) W. Kim et al.   PHARMACOLOGICAL REVIEWS

AMH (Australian Medicines Handbook, 2007 Edition)

(2007) S E Tett   CLINICAL PHARMACOLOGY & THERAPEUTICS

Postmenopausal Hormone Therapy for Disease Prevention: Have We Learned Any Lessons from the Past?

(2007) J E Rossouw   CLINICAL PHARMACOLOGY & THERAPEUTICS